{
    "address": "Drottninggatan 65",
    "city": "Stockholm",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W1R16L117",
    "description": "Annexin Pharmaceuticals AB operates as a biotechnology company. The company is headquartered in Stockholm, Stockholm and currently employs 4 full-time employees. The company went IPO on 2017-04-19. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The firm maintains a cell line for manufacture of Annexin A5. The Company\u2019s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.",
    "employeeTotal": "4.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Pharmaceuticals",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Pharmaceuticals",
    "gsector": "Health Care",
    "gsubind": "Pharmaceuticals",
    "ipo": "2017-04-19",
    "isin": "SE0009664154",
    "logo": "",
    "marketCapitalization": 149.7877,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Annexin Pharmaceuticals AB (publ)",
    "phone": "46746544644614.0",
    "sedol": "BDZT4J9",
    "shareOutstanding": 70.734528,
    "state": "STOCKHOLM",
    "ticker": "ANNX.ST",
    "weburl": "http://www.annexinpharma.com/"
}